| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | NNE; PPH; MPB1; ENO1L1; HEL-S-17 |
| Entrez GeneID | 2023 |
| WB Predicted band size | Calculated MW: 47 kDa; Observed MW: 47 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human ENO1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于ENO1抗体的3篇参考文献的模拟示例(基于已有研究主题，非真实文献，仅供参考)：
---
1. **文献名称**：*Autoantibodies against ENO1 in serum of pancreatic cancer patients: diagnostic and prognostic implications*
**作者**：Capello, M. et al.
**摘要**：该研究分析了胰腺癌患者血清中抗ENO1抗体的存在，发现其可作为潜在的诊断标志物，并与肿瘤分期和预后相关。
2. **文献名称**：*ENO1 autoantibodies contribute to autoimmune pathogenesis in systemic lupus erythematosus*
**作者**：Pratesi, F. et al.
**摘要**：研究揭示了抗ENO1抗体在系统性红斑狼疮(SLE)患者中的高表达，并探讨其通过干扰细胞代谢和促进炎症反应的致病机制。
3. **文献名称**：*ENO1 overexpression promotes tumor progression via glycolysis activation and immune evasion*
**作者**：Terrié, E. et al.
**摘要**：研究显示，ENO1在多种癌症中高表达，通过增强糖酵解和抑制抗肿瘤免疫反应驱动肿瘤进展，提示其作为治疗靶点的潜力。
4. **文献名称**：*Cross-reactivity of anti-streptococcal antibodies with human ENO1 in post-infectious autoimmune disorders*
**作者**：Astrinidis, S. et al.
**摘要**：该文献提出链球菌感染后产生的抗体可能与人类ENO1发生交叉反应，导致风湿热等感染后自身免疫疾病的发病机制。
---
**注**：以上为根据ENO1相关研究领域常见主题生成的模拟参考文献，实际文献需通过PubMed或学术数据库检索确认。
The ENO1 antibody targets alpha-enolase (ENO1), a multifunctional glycolytic enzyme encoded by the *ENO1* gene. ENO1 catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate during glycolysis, playing a critical role in cellular energy production. Beyond metabolism, ENO1 localizes to the cell surface and extracellular matrix, participating in diverse non-glycolytic processes such as cell migration, hypoxia adaptation, and immune regulation. It also acts as a plasminogen receptor, facilitating fibrinolytic activity and tissue remodeling.
ENO1 autoantibodies are implicated in autoimmune disorders. In systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and autoimmune retinopathy, these antibodies may arise due to molecular mimicry triggered by infections (e.g., *Streptococcus* or *Candida*), leading to cross-reactivity with human ENO1. Elevated ENO1 antibody levels correlate with disease severity, suggesting diagnostic or prognostic utility.
In cancer, ENO1 is overexpressed in tumors (e.g., lung, breast, pancreatic), promoting metastasis and chemoresistance. ENO1 antibodies are explored as biomarkers for early detection or therapeutic targets. However, their role remains complex, as ENO1 exhibits both tumor-suppressive and oncogenic behaviors depending on context. Research continues to unravel its dual functions and therapeutic potential.
×
